Letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by P. Barrière, S. Hamamah, E. Arbo, C. Avril, B. Salle, J.-L. Pouly, et al. (J Gynecol Obstet Hum Reprod. 2023;52(1):102510)

other OA: green CC-BY-4.0
AI-generated summary by claude@2026-06, 2026-06-12

This letter to the editor responds to a real-world study comparing a biosimilar rFSH against the originator, discussing its findings in the context of differing rFSH starting doses.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-21T06:12:49.409960+00:00
pubmed
last seen: 2026-06-21T06:11:38.412952+00:00
unpaywall
last seen: 2026-05-15T02:00:00.661756+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine